Title: Pyronaridine Tetraphosphate Efficacy Against Ebola Virus Infection in Guinea Pig

Short running title: Pyronaridine efficacy against Ebola virus

Authors: Thomas R. Lane^{a†}, Christopher Massey^{b†}, Jason E. Comer^{b,c,d}, Alexander N. Freiberg^{d,e}, Huanying Zhou^f, Julie Dyal^f, Michael R. Holbrook^f, Manu Anantpadma^{g\$}, Robert A. Davey^{g#}, Peter B. Madrid^h and Sean Ekins^{a#}

Affiliations: ^a Collaborations Pharmaceuticals, Inc., 840 Main Campus Drive, Lab 3510, Raleigh, NC 27606, USA.

^b Institutional Office of Regulated Nonclinical Studies, University of Texas Medical Branch, 301 University Blvd., Galveston, TX 77555, USA

^c Department of Microbiology and Immunology, University of Texas Medical Branch, 301 University Blvd., Galveston, TX 77555, USA

^d Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, 301 University Blvd., Galveston, TX 77555, USA

^e Department of Pathology, University of Texas Medical Branch, 301 University Blvd., Galveston, TX 77555, USA

^f Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD, USA

20 ^g Texas Biomedical Research Institute, San Antonio, TX 78227, USA.

21 ^h SRI International, 333 Ravenswood Avenue, Menlo Park, CA 94025, USA.

22

23 ^{\$}Current address: Boston University, National Emerging Infectious Diseases
24 Laboratories, 401P, 620 Albany Street, Boston, MA 02118.

25 #To whom correspondence should be addressed: Sean Ekins, E-mail address:
26 sean@collaborationspharma.com, Phone: +1 215-687-1320

27 [†] Co-first authors, identified alphabetically by SE.

28

29

30

Abstract

The recent outbreaks of the Ebola virus (EBOV) in Africa have brought global visibility to the shortage of available therapeutic options to treat patients infected with this or closely related viruses. We have recently computationally identified three molecules which have all demonstrated statistically significant efficacy in the mouse model of infection with mouse adapted Ebola virus (ma-EBOV). One of these molecules is the antimalarial pyronaridine tetraphosphate (IC₅₀ range of 0.82-1.30 μ M against three strains of EBOV and IC₅₀ range of 1.01-2.72 μ M against two strains of Marburg virus (MARV)) which is an approved drug in the European Union and used in combination with artesunate. To date, no small molecule drugs have shown statistically significant efficacy in the guinea pig model of EBOV infection. Pharmacokinetics and range-finding studies in guinea pigs directed us to a single 300mg/kg or 600mg/kg oral dose of pyronaridine 1hr after infection. Pyronaridine resulted in statistically significant survival of 40% at 300mg/kg and protected from a lethal challenge with EBOV. In comparison, oral favipiravir (300 mg/kg dosed once a day) had 43.5 % survival. The *in vitro* metabolism and metabolite identification of pyronaridine and another of our EBOV active molecules, tilorone, which suggests significant species differences which may account for the efficacy or lack thereof, respectively in guinea pig. In summary, our studies with pyronaridine demonstrates its utility for repurposing as an antiviral against EBOV and MARV, providing justification for future testing in non-human primates.

Importance

There is currently no antiviral small molecule drug approved for treating Ebola Virus infection. We have previously used machine learning models to identify new uses for approved drugs and demonstrated their activity against the Ebola virus *in vitro* and *in vivo*. We now describe the pharmacokinetic properties of the antimalarial pyronaridine in the guinea pig. In addition, we show that this drug is effective against multiple strains of EBOV and MARV *in vitro* and in the guinea pig model of Ebola virus infection. These combined efforts indicate the need to further test this molecule in larger animal efficacy studies prior to clinical use in humans. These findings also may be useful for repurposing this drug for use against other viruses in future.

Keywords: Antiviral, Ebola virus disease, Favipiravir, Guinea Pig, Pyronaridine

Introduction

Repurposing drugs for different diseases offers the opportunity to take a molecule that is approved for one clinical use and apply it to another disease, potentially accelerating its application and approval (1-3). There have been many articles on this approach and its successes (4). Several examples demonstrate repurposing compounds for the Ebola virus (EBOV) (5-7) which is a member of the virus family *Filoviridae* and pathogenic in both humans and non-human primates, causing severe hemorrhagic fevers (8) with mortality rates as high as 90% (9, 10). The recent outbreaks of EBOV in Africa have highlighted the need for new antiviral drugs for this and other emerging viruses to counter the human and financial cost (11, 12). The outbreak in Western Africa in 2014-2016 killed over 11,000 and caused over \$53bn in economic damage (13). The current ongoing outbreak in the Democratic Republic of the Congo, in which well over 2200 people have died to date at the time of writing, and where the current case fatality is ~67% (14)), emphasizes this need for new drugs while there is still no FDA approved drug for this disease. Several small molecule drugs such as favipiravir (15, 16) and most recently remdesivir (17) have been tested against EBOV in patients, although it is unclear whether any of them demonstrate efficacy (18, 19). We have previously used a computational approach with a published high-throughput screen of 868 molecules tested in a viral pseudotype entry assay and an EBOV replication assay (20, 21). This computational model enabled us to virtually screen several thousand compounds and identify three active compounds: tilorone, quinacrine and pyronaridine (22). All of these molecules inhibited EBOV in HeLa cells but not Vero cells, and they all demonstrated significant *in vivo* activity in the mouse-adapted EBOV (ma-EBOV) efficacy model (23-

25). Pyronaridine (EC₅₀ range of 420 nM-1.14 μ M (22, 26)) has been previously described in detail (27). It is the major component of the EU-approved antimalarial Pyramax, which is a combination antimalarial therapy with artesunate and pyronaridine and is approved for this use in the Democratic Republic of the Congo as well as other countries (e.g. South Korea). Our recent assessment of pyronaridine treated ma-EBOV-infected mice in range-finding studies indicated that a single 75 mg/kg i.p. dose which when given 1hr after infection resulted in 100% survival and statistically significantly reduced viremia on study day 3 (25). Additional studies in ma-EBOV-infected mice demonstrated that we could dose pyronaridine (75 mg/kg) 2 or 24hrs post-exposure without affecting survival (25). This was mirrored in our previous tilorone EBOV mouse study with treatment doses at 30 mg/kg q.d. (23). The pyronaridine mouse efficacy study also provided preliminary insights into how pyronaridine may possess antiviral activity as cytokine and chemokine panels suggested immunomodulatory actions during an EBOV infection (25). Our recent follow-up studies with the structurally related quinacrine (24) indicated this and many other structurally related antimalarials are active against EBOV *in vitro* (25) and may have a similar mechanism of action as all are known or suspected to be lysosomotropic amines. Such lysosomotropic compounds can diffuse across the membranes of acidic cytoplasmic organelles in their unprotonated form, then become protonated in the acidic environment, causing substantial accumulation in these organelles (28), which has the potential to ultimately impact lysosomal function.

It should be pointed out that there are many FDA approved drugs for which the mechanism is unknown. It is only in recent years that we have started to unravel the mechanism of action of such drugs that were approved decades ago (29, 30). The focus of our current efforts is on assessing pyronaridine and other clinical stage compounds as possible treatments for EBOV. Our studies to date with tilorone, quinacrine and pyronaridine may also provide compounds which could be combined as EBOV therapies for future assessment. While the focus of this study is testing pyronaridine, tilorone was also evaluated alongside favipiravir in the guinea pig model of EBOV infection to assess whether the efficacy observed in mouse would also be observed in this species. *In vivo* studies in the guinea pig would if successful then lead the way for studies in non-human primates.

Results

Testing vs EBOV and MARV strains. Pyronaridine, tilorone, and quinacrine were all previously discovered using machine learning models for EBOV and tested against the Mayinga strain (22). We now demonstrate that they block the entry stage of infection in a pseudotype assay (Fig. S1). Even though EBOV and MARV are distantly related (31) we also now show these three compounds are active against MARV Musoke strain in HeLa Cells (Fig. S2). These compounds were found by two of our groups to be similarly efficacious against multiple EBOV (Kikwit, Mayinga and Makona) and MARV (Musoke and Angola) (Fig. 1 and Table 1) strains in HeLa cells.

Metabolic stability across species. We have previously characterized the *in vitro* metabolic stability of pyronaridine in mouse, guinea pig, non-human primate and human (25). We have now performed a comparison for tilorone, quinacrine and chloroquine (a known lysosomotropic compound (32)) under similar conditions. Pyronaridine liver microsome (LM) metabolic stability increased in the order of guinea pig, non-human primate, human and then mouse. Tilorone had a similar species-LM stability relationship, with an increase in the order of guinea pig, non-human primate, mouse, followed by human. Chloroquine differed, with LM metabolic stability in the order of mouse, non-human primate, guinea pig and then human. Finally, quinacrine metabolic stability increased in the order of non-human primate, mouse, guinea pig and then human (Table 2). The CYP2D6 substrate probe dextromethorphan metabolism closely paralleled the species differences observed for pyronaridine and was also used to normalize the $t_{1/2}$ (Table S1 and S2).

Metabolite identification across species. We have previously characterized the pyronaridine metabolites produced in mouse microsomes (25). We have now evaluated the metabolites of multiple compounds with *in vitro* activity against EBOV (pyronaridine, tilorone, quinacrine and chloroquine) across multiple species (human and guinea pig) (Fig. S3-S6). The relative peak area abundance (%) for pyronaridine mono-oxygenation was much higher in guinea pig as compared to human liver microsomes. Tilorone *N*-deethylation and mono-oxygenation was higher in guinea pig relative to both mouse and human. Quinacrine O-demethylation was also 2-3 times higher in guinea pig. In contrast, chloroquine mono-oxygenation was highest in mouse relative to other

species. Overall, guinea pig metabolism for these compounds in LMs differed substantially as compared to the other species tested.

Guinea pig dose range-finding toxicity. The maximum tolerated dose of pyronaridine was evaluated in Hartley guinea pigs (Fig. 2). In the pyronaridine i.p.-dosed groups the highest dose level of 300 mg/kg was acutely toxic, with 4 of 6 guinea pigs found dead within 30 mins post injection. In addition, one died on day 7 and surprisingly the final surviving guinea pig showed no abnormal clinical observations. For the 200 mg/kg i.p.-dosed guinea pigs, 2 of 6 were found dead on days 5 and 6 and one met criteria for euthanasia on day 6. The remaining surviving guinea pigs from this group were found prostrate on day 7 (Fig. 2D). No abnormal clinical observations were noted for guinea pigs administered either 125 mg/kg pyronaridine or vehicle via i.p. administration for the duration of the study. Oral dosing however had drastically reduced toxicity, with only 1 of 6 having any abnormal clinical observations at 600 mg/kg, which was detected directly following administration. This animal was found breathing rapidly for 6 mins, but fully recovered 2 hr post dose. There were no abnormal clinical observations at 300 or 125 mg/kg via oral administration. Based on these results, the maximum tolerated dose (MTD) for a single pyronaridine dose was determined as 125 and >600 mg/kg for i.p. and oral administration, respectively (Fig. 2A). Additionally, the maximum tolerated dose of tilorone was also tested in guinea pigs (Supplemental Methods, Supplemental results, Fig. S7A).

Guinea pig pharmacokinetics evaluation of pyronaridine.

The pharmacokinetics of pyronaridine was evaluated in Hartley guinea pigs (Fig. 2C, F). After an initial rapid absorption phase, the pyronaridine plasma profile exhibited a distribution phase at about 1hr, then a prolonged phase with plasma drug concentrations remaining essentially unchanged, or slightly higher until about 72hrs. All samples for animals dosed orally and i.p. contained measurable levels of pyronaridine though 336 and 168 hrs, respectively (LLOQ = 1 ng/ml). The plasma drug levels were analyzed using noncompartmental modeling allowing for the calculation of pharmacokinetic parameters (Table 3). Pyronaridine plasma levels reached the peak in the first sample, taken at 1 hr post administration. The elimination-phase $t_{1/2}$ was calculated as 72.7 and 90.5 hrs for i.p. and oral administration, respectively. This is considerably shorter than the $t_{1/2}$ found in humans and mice of between 195-251 hrs (33, 34) and 146 hrs (25), respectively. Maximum concentration of unbound drug in plasma (C_{max}), area under the concentration-time curve from time zero to the last measurable concentration (AUC_{last}), and area under the concentration-time curve from time zero to infinity (AUC_{inf}) are provided in Table 3. Additionally, the pharmacokinetics of tilorone was also evaluated in guinea pigs (Supplemental Methods, Supplemental results, Fig. S7B, C and S8).

Pyronaridine efficacy and clinical observations.

The efficacy of pyronaridine was evaluated in Hartley guinea pigs challenged with guinea pig adapted EBOV (gpa-EBOV). All animals in vehicle treatment (Group 1) succumbed to disease by study day 12 (100% mortality). Group 2 (pyronaridine 300 mg/kg) and Group 3 (pyronaridine 600

mg/kg) resulted in 40% and 33% survival, respectively. Among the 16 animals in the combined Group 4 (favipiravir 300 mg/kg), 7 GPs survived through the end of the 21-day study period; the other 9 guinea pigs succumbed to disease by study day 14 (43.75% survival, Fig. 3A). It should be noted that an animal in Group 2 was euthanized due to a clinical score of 4 on study day 2. Ebola disease in guinea pigs does not progress this rapidly so it is unlikely the animal succumbed to disease and it is more likely the animal incurred esophageal trauma because of the oral gavage technique, therefore this animal has been removed from data analysis.

Body weight results for each treatment group are summarized in Fig. 3B. Animals in Group 1 maintained body weight through study day 7 but decreased by study day 10, when all animals succumbed to disease. Group 2 animals body weight continuously decreased through study day 7, with surviving animals returning to pre-challenge body weights by study day 10. Group 3 animals dropped body weight following challenge, but the survivors reverted to pre-challenge body weight by the end of the 21-day study. It should be noted that an animal in this group had developed clinical signs late and succumbed to infection on study day 17. Animals in Group 4 remained at a consistent body weight until study day 10 where the mean body weight began to decrease briefly, but the surviving animals rebounded to pre-challenge weight by study day 13.

Plaque assay results from serum samples taken from animals that met euthanasia criteria during the scheduled observation times from all four groups are presented in

Fig. 3D. Only 10 of the 20 terminal samples had detectable levels of viable gpa-EBOV: eight animals from Group 1 (4.87×10^7 geometric mean PFU/mL) and two animals from Group 2 (8.15×10^5 geometric mean PFU/mL). Interestingly, all the guinea pigs treated with favipiravir were below the limit of detection for the plaque assay (Fig. S9).

Clinical scoring results for each guinea pig was assessed on a scale ranging from 1-4, where a score of 1 indicated a healthy animal and a score of 4 was indicative of a moribund animal. All animals in each group succumbed at least partially to disease by study day 8 (Fig. 3A). In each group the mean clinical observation increased inversely with survival, with each pyronaridine-treated group having two independent increases in average clinical observations. Interestingly, during post-study day 8 the average clinical score in the favipiravir group seemed to be independent of survival (Fig. 3C).

Favipiravir and Pyronaridine *in vivo* efficacy against EBOV. It should be noted that in order to increase the statistical power of our study we combined the favipiravir, positive-control data from our two individual experiments (n=6, n=10) as these used comparable approaches and were performed by the same group. Due to the small group sizes the data for the negative, vehicle controls (n=6, n=10) were also combined with the noted caveat of a variation in frequency of administration.

Favipiravir has been shown to protect guinea pigs from adapted Sudan Virus (35) however in our study it protected ~44% of the animals against gpa-EBOV, with deaths

starting on study day 6 and continuing until study day 14 (Fig. 3A). These were not statistically different from the treatment with pyronaridine 300 and 600 mg/kg with 40% and 33% survival, respectively (Log-rank (Mantel-Cox) test). Tilorone at the doses assessed were either comparable or had significantly reduced survival rates as compared to the vehicle (Fig. S9A). In summary, there was a statistically significant difference for both pyronaridine (300 mg/kg) and favipiravir when compared to the control combined from our two studies (Fig. 3).

The results in guinea pig are surprising as previous studies in mouse have shown pyronaridine, tilorone and favipiravir all protect mice infected with ma-EBOV (24, 25, 36). Interestingly, virus was only detected in serum samples collected at the time of euthanasia from one and two Guinea pigs from the vehicle and pyronaridine 300 mg/kg, respectively, in the current pyronaridine study. This differed in our tilorone study (Supplemental Methods, Supplemental Results, Fig. S7-S9) where virus was recovered from all but one serum sample harvested from the guinea pigs in the vehicle and tilorone-treated groups (Fig. S9D). Virus was not detected in guinea pigs treated with favipiravir (both survivors and non-survivors) and was statistically significantly reduced from vehicle (Fig. 3D).

Discussion

There have been very few small molecule drugs that have reached the clinic for testing against EBOV, including favipiravir (37), GS-5734 (remdesivir) (17) and

galidesivir (17). Favipiravir has demonstrated 100% efficacy in the mouse model of EBOV (38, 39), 83% protection in the Interferon α/β and γ Double Knockout Mice mouse model (40), 17% (41) to 50% (42) survival in the cynomolgous macaque and increased survival and decreased viral load (43) or unclear efficacy in humans (15, 16). Once daily IV dosed remdesivir has demonstrated 100% survival in non-human primates only (44) and on this basis has been tested in humans during the current EBOV outbreak. Recently, a significant portion of data was described (499 individuals) from a clinical trial involving the investigation of multiple therapeutics against EBOV (NCT03719586) with ZMapp (a monoclonal antibody cocktail) (45)), remdesivir, MAb114 (a monoclonal antibody) (46)) and REGN-EB3 (monoclonal antibody combination) (47)). These results showed that the antibodies REGN-EB3 and mAb114 had overall survival rates of 71% and 66%, respectively, and were much more effective with patients with low viremia levels. Both ZMapp and remdesivir were shown to be less effective with a 51% and 47% survival rates, respectively (19). Ebola generally has a wide variation in its fatality rates of between 25% to 90%, (average ~50%). While these results are promising for the monoclonal antibodies, the delivery and administration of likely temperature sensitive treatments to remote areas in Africa is a potential issue. A highly stable small molecule drug that could be given orally as a single dose would be ideal and alleviate some of these logistical challenges that constitute the critical final stage of delivering a therapeutic to the patient.

From this present study, pyronaridine and several other drugs which we have identified have shown activity in several strains of EBOV and MARV *in vitro* (Fig. 1 and Table 1),

indicating they may have a broad-spectrum activity against the virus family *Filoviridae*. Based on our pseudovirus data these would appear to be preventing entry of the virus (Fig. 1). Two of these drugs were studied further in the guinea pig model of EBOV infection. It is apparent that pyronaridine did not show as substantial of a difference in the survival rate in guinea pig as was observed for mouse (100% survival) (25). This may be because the half-life for pyronaridine is much shorter in the guinea pig, so efficacious plasma levels of drug are likely not maintained long enough (90 hrs). The pharmacokinetics varies in other species, where the half-life in mice and humans is approximately 140 hrs and 200 hrs, respectively. Many other small molecules have failed to progress beyond guinea pig for EBOV due to a lack of significant efficacy (7, 48-51). While antibodies have been successfully used in this animal model (52, 53), these failures may represent a significant limitation of the guinea pig model to extrapolate small-molecule efficacy against EBOV in humans. We have demonstrated there are substantial metabolic stability differences between mouse, non-human primate, human and guinea pig (25), with the latter having a considerably lower metabolic stability for pyronaridine (Table 2). This could be one explanation of why several drugs for EBOV perform well in mouse but fail in the guinea pig. While to our knowledge this has not been determined for favipiravir, it has been shown that the pharmacokinetics of this compound exhibit nonlinearity over dose and time in non-human primates (54), making these interspecies' comparisons potentially much more complex. Based on this *in vitro* data it would also suggest the metabolic stability of pyronaridine in the non-human primate may also be poor, requiring a dose adjustment to retain efficacy in this model. Antibody therapeutics for EBOV are not likely to be

313 metabolized by the same drug metabolizing enzymes; therefore, they may show more
 314 universal efficacy across species. We have also evaluated the metabolism of several
 315 drugs of interest in liver microsomes of various species under similar conditions (Table
 316 2). The structurally unrelated tilorone also appears to have limited metabolic stability in
 317 guinea pig and is much more stable in non-human primate and human liver
 318 microsomes. Chloroquine and quinacrine show different patterns across species. Our
 319 comparison of metabolic stability with the substrate probe dextromethorphan may also
 320 point to the role of CYP2D family in the metabolism of pyronaridine. It has previously
 321 been shown that pyronaridine inhibits known substrates of CYP2D6 both *in vitro* (25)
 322 and *in vivo* (55), also suggesting that it may be a CYP2D6 substrate as well. We have
 323 supplemented these data with detailed metabolite identification for each of these four
 324 compounds available for the first time (Figure S3-6). It is unclear what effect EBOV
 325 infection would have on the metabolic enzymes such as the P450's in the guinea pig.
 326 To our knowledge, favipiravir has not previously been tested orally against EBOV in
 327 guinea pig (though it has demonstrated survival rates of 83-100% in Sudan virus-
 328 infected guinea pigs (35)), and in this study we now demonstrate efficacy on a par with
 329 what was observed in non-human primates (41, 42). In comparison, survival after
 330 pyronaridine (300 and 600 mg/kg) treatment was not significantly different from oral-
 331 administered favipiravir in the guinea pig model ((Log-rank (Mantel-Cox) test),
 332 suggesting a similar efficacy. There was a statistically significant difference for both
 333 pyronaridine (300 mg/kg) and favipiravir when compared to the control combined from
 334 our two studies (Fig. 3). Our initial dose ranging work showed significant toxicity with
 335 pyronaridine when dosed i.p. in guinea pig (accumulation in the abdominal cavity)

hence the focus on oral administration in this study. It should be noted that we used only a single dose of pyronaridine for all our efficacy studies, and it is feasible that more frequent dosing to overcome the lower half life may result in a higher exposure and subsequent increased survival rate.

Developing small molecule drugs for EBOV is extremely challenging. While high throughput screens have readily identified many FDA approved drugs as well as other candidate molecules with *in vitro* inhibitory activities against EBOV (20, 56), when these compounds are tested in guinea pig, to date, all of them have failed. For example, chloroquine (7, 48), azithromycin (7), amiodarone (49), iminosugars (50), BGB324 (51), NCK8 (51) and 17-DMAG (51) were all inactive in the guinea pig *in vivo* model. Interestingly, tilorone (57), chloroquine (32), azithromycin (58), amiodarone (59), BGB324 (60) and 17-DMAG (61) are all known lysosomotropic compounds and NCK8 is most likely as well (62). This may indicate that these compounds could have also failed due to a common antiviral mechanism that does not transcend species. In addition, there is recent evidence that the type-I IFN antiviral immune response in guinea pig is significantly different than in mouse or non-human primate (63), therefore guinea pig may not be an appropriate model to universally predict the antiviral response in humans. This is particularly relevant to EBOV, since viral susceptibility and adaptation to guinea pig was directly linked to differences in the immune response (64).

In total, these results for pyronaridine, tilorone and favipiravir may question the need for demonstrating efficacy against gpa-EBOV before expanding to the non-human primate model of Ebola virus infection. They also suggest that larger group sizes are required to show statistical significance and to allow for spontaneous animal deaths due to issues with oral gavage, which ultimately reduces animal group sizes.

In conclusion, the guinea pig *in vivo* data collected in this study points to ~40% survival for pyronaridine and favipiravir against gpa-EBOV. The accumulated *in vitro* metabolic data indicates that the guinea pig may be a suboptimal model to predict the efficacy of these compounds to combat EBOV. This could be due to differences in EBOV mechanism and drug metabolism (e.g. species differences in the metabolic enzymes involved (65, 66)). Our combined *in vitro* and *in vivo* studies with pyronaridine demonstrate its potential utility for repurposing as an antiviral against different strains of EBOV and MARV. These efforts also provide ample justification for future testing of pyronaridine efficacy in non-human primates and possible provision of the combination drug Pyramax for future Ebola outbreaks.

MATERIALS AND METHODS

Ethics statement. All work with gpEBOV-challenged guinea pigs was approved by the University of Texas Medical Branch's IACUC (IACUC protocol number 1805041 approved 5th June 2018) and was done in accordance with all applicable sections of the

Final Rules of the Animal Welfare Act regulations (9 CFR Parts 1, 2, and 3) and *Guide for the Care and Use of Laboratory Animals: Eighth Edition* (Institute of Laboratory Animal Resources, National Academies Press, 2011; the *Guide*). This work was conducted in UTMB's AAALAC (Association for the Assessment and Accreditation of Laboratory Animal Care)-accredited GNL BSL4 laboratory.

Chemicals and reagents. Pyronaridine tetraphosphate [4-[(7-Chloro-2-methoxybenzo[b][1,5]naphthyridin-10-yl)amino]-2,6-bis(1-pyrrolidinylmethyl)phenol phosphate (1:4)] (22) was purchased from BOC Sciences (Shirley NY). Favipiravir was purchased from AdooQ Bioscience (Irvine, CA). Tilorone and pyronaridine was purchased from BOC Sciences. Quinacrine and Chloroquine were purchased from Cayman Chemicals (Ann Arbor, Michigan) and Sigma Aldrich (St. Louis, MO), respectively.

***In Vitro* ADME assays.** *In vitro* ADME studies were performed by BioDuro (San Diego, CA).

***In Vitro* liver microsome stability assays.** The liver microsome solution (197.5 µL, 0.5 mg/ml protein concentration) (Sekisui Xenotech, Kansas City, KS) was aliquoted into 1.1 ml tubes, to which 2.5 µL of positive control and test compound stock solutions (100 µM in DMSO) were added. The tubes were vortexed gently, pre-incubated for 5 min at 37°C, then 50 µL of 5 mM NADPH or LM buffer (no NADPH buffer) was added

into the tubes. For analysis, an aliquot of 30 μ L was removed from each tube at 0, 5, 15, 30 and 60 min (without-NADPH reaction:0 and 60 min) and quenched with 300 μ L of 5/10 ng/ml terfenadine/tolbutamide in methanol/acetonitrile (1:1, v/v). Samples were vigorously vortexed for 1 min and then centrifuged at 4,000 rpm for 15 min at 4°C. 100 μ L of supernatant from each sample was transferred to tubes for LCMS analysis. The amount of parent compound was determined on the basis of the peak area ratio (compound area to IS area) for each time point (AB SCIEX 4500). Clearance rates were calculated by the equation: $t_{1/2} = \ln(2)/k_e$ and in vitro CL_{int} (μ L/min/mg protein) = $k_e \times \text{Incubation volume} / \text{Microsomal protein amount}$, and k_e using equation of 1st order kinetics :

***In Vitro* Metabolite Identification of pyronaridine, quinacrine, chloroquine and tilorone in human, mouse, guinea pig liver microsomes.** A DMSO solution of test compound was spiked into 50 mM KH_2PO_4 (pH 7.4) buffer containing liver microsome at a concentration of 1 mg/mL (Sekisui Xenotech, Kansas City, KS). The reaction was initiated by the addition of 1.0 mM NADPH to the reaction mixture. The final concentration of the test compound was 1 μ M. After 0 min and 60 min incubation at 37°C, an aliquot was removed and the sample were precipitated with a 1:6 acetonitrile, quenching the reaction. The resulting mixture was centrifuged, and the resultant supernatants were dried at N_2 stream, the resultant residue were reconstituted with 300 μ L 10% acetonitrile/ H_2O (v/v) (0.1% FA) before LC-MS/MS analysis. The supernatant was used for LC-MS/MS analysis. All separations were performed on a ACQUITY UPLC BEH T3 1.8 μ m column (2.1 $\times$ 100 mm) at 25°C with a flow rate of 0.3

mL/min. Mobile phase A consisted of 0.1% formic acid in water and mobile phase B consisted of 0.1% formic acid in acetonitrile. Chromatography used a step gradient by maintaining 1% mobile phase B for 5 min, 10% mobile phase B over 8.0 minutes, 20% mobile phase B over 2.0 min, 90% mobile phase B over 2 minutes, 95% mobile phase B over 2 minutes, then re-equilibration back to 1% B at 20 minutes. The total run time was 22 minutes. For all samples, a 5 µL aliquot of sample was injected. The mass spectrometer (HRMS, Q-Exactive Plus from Thermo Fisher) was operated in high-resolution, accurate-mass (HRAM) Orbitrap detection mode.

Test article preparation for *In Vivo* studies. Vehicle Preparation (Pyronardine study): A solution of 20% Kolliphor HS 15 with Water for injection (WFI) was made to be used for the vehicle. Kolliphor HS 15 was melted at 60 °C. 10 ml of Kolliphor HS 15 was combined with WFI to a final solution volume of 50.0 ml (20% solution) and mixed using a vortex mixer for 30 seconds and then sonicated in an ultrasonic water bath for 25 minutes at 45°C. Test Article Dose Preparation: Dose formulations were prepared by mixing the pyronaridine in the vehicle to achieve the target concentration. The formulation was mixed by inversion 5-6 times and placed on an orbital shaker for 30±5 min. Favipiravir Preparation: A 0.5% solution of methylcellulose was prepared in sterile water. To this, the appropriate amount of Favipiravir was added, and the pH adjusted until the compound goes into solution. Favipiravir was prepared prior to challenge and stored at 4-8 °C.

Guinea pig *in vivo* dose range-finding toxicity for pyronaridine. To assess

the tolerance of pyronaridine and to select dose groups for pharmacokinetics studies, the drug was given to 5-6-week-old male and female Hartley guinea pigs (Vital River Laboratories) as a single dose by intraperitoneal (i.p.) administration or oral gavage (PO). The compound was formulated in 20% Kolliphor HS 15 (Solutol) in sterile water. There were 8 groups in total (i.p. and oral control groups), with 6 animals per group (3 male, 3 female). I.p. administration was 125, 200 and 300 mg/kg and oral was 125, 300 and 600 mg/kg, each with a dosing volume of 5 ml/kg. Clinical observations were initiated immediately post-dose and once daily up to 168 hrs post-dose.

Guinea pig *in vivo* pharmacokinetics evaluation of pyronaridine. Guided by

the dose range-finding study, the pharmacokinetics of pyronaridine in guinea pigs were initially assessed at 125 and 600 mg/kg (n=3; male) for i.p. and oral administration, respectively, concentrations at or below the MTD determined by the 7-day study. Pyronaridine for both oral and i.p. administration was solubilized in the same vehicle (20% Kolliphor HS 15). Blood was collected from the treated Guinea pigs at 1, 4, 8, 24, 72, 168, 264 and 336 hrs post-dose for processing of plasma. All samples were analyzed, and drug levels were measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS) with a lower limit of quantitation (LLOQ) of 1.0 ng/mL. Notably, in the pyronaridine i.p. dosed, 125 mg/ml group 2 of 3 Guinea pigs were found dead on days 14 and 17 post dose.

Virus strains. For *in vivo* experiments, a well-characterized guinea pig-adapted Ebola virus stock (Ebola virus *Cavia porcellus*/ COD/1976/Mayinga-CDC-808012 (gpaEBOV)) was used for all efficacy studies (67). All work involving infectious gpa-EBOV was performed at the Galveston National Laboratory (GNL) biosafety level (BSL) 4 laboratory, registered with the Centers for Disease Control and Prevention Select Agent Program for the possession and use of biological select agents.

Initial cell-based testing for inhibition against wild type MARV strain. MARV expressing GFP was used in testing against viral inhibition as outlined previously (31). In short, inhibitors were tested at 8 concentrations for activity. All treatments were done in duplicates, each replicate being on a different plate. Briefly, 4,000 HeLa cells (Ambion, Austin, TX) per well in 25 μ l of medium were grown overnight in 384-well tissue culture plates. On the day of assay, test compounds were diluted to 200 μ M concentration in complete medium. 25 μ l of this mixture was added to the cells already containing 25 μ l medium to achieve a concentration of 100 μ M. 25 μ l of medium was removed from the first wells and added to next well. This type of serial dilution was done 8 times to achieve concentrations of 100, 50, 25, 12.50, 6.25, 3.12, 1.56 and 0.78 μ M. One hour after incubating with the compound 25 μ l of infection mix containing wild type virus was used to infect cells. This resulted in a final concentration of 50, 25, 12.50, 6.25, 3.12, 1.56, 0.78 and 0.39 μ M. Bafilomycin at final a concentration of 10 nM was used as a positive control drug. All virus infections were done in a BSL-4 lab to achieve a MOI of 0.075 to 0.15. Cells were incubated with virus for 24 hours. One day post infection cells were fixed by immersing the plates in formalin overnight at 4°C. Fixed

plates were decontaminated and brought out of the BSL-4. Formalin from fixed plates was decanted and plates were washed thrice with PBS. MARV infected plates were immuno-stained using virus specific antibodies. Nuclei were stained using Hoechst at 1:50,000 dilutions. Plates were imaged and nuclei and infected cells were counted using Cell Profiler software.

Cells were permeabilized using 0.1% Triton X-100 (Sigma, Cat#T8787) in PBS and blocked for 1 h in 3.5% bovine serum albumin (Fisher-scientific- Cat#BP9704100), followed by immunostaining. Fixed cells were incubated with an anti-MARV VLP antibody (IBT bioservices, Cat#04-0005, 1:1500 dilution), overnight at 4°C. After 2 washes to remove any excess antibody cells were stained with anti-Rabbit Alexa-546 antibody (Life technologies, Cat#A11035). After 3 washes to remove any non-specific antibody nuclei were stained using Hoechst at 1:50,000 dilution and imaged on a Nikon Ti Eclipse automated microscope. Nuclei and infected cells were counted using CellProfiler software. Relative infection compared to untreated controls was plotted in GraphPad prism 8.2.1 software.

Follow-up cell-based testing against EBOV and MARV strains. Compounds were tested in vitro against 3 strains of Ebola virus (Kikwit, Makona, Mayinga) and 2 strains of MARV (Angola, Musoke): Ebola virus/H.sapiens-tc/GIN/2014/Makona-C05 (EBOV/Mak, GenBank accession no. KX000398.1), Ebola virus/H.sapiens-tc/COD/1995/Kikwit-9510621 (EBOV/Kik, GenBank accession no. KU182905.1); Ebola

virus/H.sapiens-tc/COD/1976/Yambuku-Mayinga (EBOV/May, GenBank accession no. KY425649.1); Marburg virus/H.sapiens-tc/AGO/2005/Ang-1379v (MARV/Ang, BioSample accession no. SAMN05916381); Marburg virus/H.sapiens-tc/KEN/1980/Mt. Elgon-Musoke (MARV/Mus, GenBank accession no. DQ217792). All virus stocks were propagated, and titers were determined by plaque assay on Vero E6 cells obtained from the American Type Culture Collection (Manassas, VA) as previously described (68).

The *in vitro* infection inhibition of the all the above filovirus strains was performed in HeLa cells. HeLa cells were seeded at 3×10^4 cells/well in 96-well plates. After 24 hours (h), cells were treated with drugs at 2-fold dilutions starting from 30 μ M. Cells were infected with virus 1 hr after the addition of the drugs in BSL4-containment at a multiplicity of infection (MOI) of 0.21 or 0.4. After 48 h, plates were fixed and virus was detected with a mouse antibody specific for EBOV VP40 protein (#B-MD04-BD07-AE11, made by US Army Medical Research Institute of Infectious Diseases, Frederick MD under Centers for Disease Control and Prevention contract) (68) or MARV VP40 protein (Cat# IBT0203-012, IBT Bioservices, Rockville, MD) followed by staining with anti-mouse IgG-peroxidase labeled antibody (KPL, Gaithersburg, MD, #074-1802). Luminescence was read on an Infinite® M1000 Pro plate reader (Tecan US, Morrisville, NC). The signal of treated, infected wells was normalized to uninfected control wells and measured (in percent) relative to untreated infected wells. Non-linear regression analysis was performed, and the 50% inhibitory concentrations (EC_{50} s) were calculated from fitted curves (log [agonist] versus response [variable slope] with constraint to remain above 0%) (GraphPad Software, La Jolla, CA). Error bars of dose-response

curves represent the standard deviation of three replicates. For quantitation of drug toxicity, HeLa cells were mock infected (no virus) and treated with drug dilutions under the same conditions as the infected cells. After 48 h, cell viability was measured using the CellTiter Glo Luminescent Cell Viability Assay kit according to manufacturer's protocol (Promega, Madison, WI).

VSV-EBOV-GP pseudotype virus assay. Vesicular Stomatitis Virus (VSV) pseudotyped with EBOV glycoprotein (GP) expressing a GFP reporter was generously provided by Dr. Wendy Maury (University of Iowa) and has been described previously (69, 70). VSV pseudotyped with EBOV glycoprotein was grown by infecting Vero cells (Ambion, Austin, TX) and then harvesting via filtration of the supernatant through 0.4 μ M filters 24-30 hours after infection. Virus was then stored at -80 until use.

The cells were tested and imaged using the general methods outlined previously (31). In short, HeLa cells (Ambion, Austin, TX) were plated at a density of 20,000 cells/well of a 96 well plate. After attachment overnight, cells were pretreated with compounds for 1 hr at predetermined doses. The dosing series in this case was 25, 12.5, 6.25, 3.12, 1.56, 0.78, 0.39, 0.19, 0.09, 0.04, 0.02 and 0.01 μ M. After 1 hr of incubation with compounds, the cells were infected with VSV pseudotyped with EBOV glycoprotein and expressing a GFP reporter. 24 hours after infection, cells were fixed in formalin. After fixation, formalin was washed off, nuclei stained with Hoechst and the cells imaged. Green cells (infected) and blue nuclei (total number of cells) were counted using cell profiler. Relative infection compared to untreated controls was plotted in GraphPad prism 8.2.1 software.

559

560 ***In Vivo* efficacy clinical observations and scoring.** Twenty-four (24)

561 experimentally naïve Hartley guinea pigs were assigned to four (4) gender balanced
562 groups. Guinea pigs were anesthetized for dosing (challenge and treatment) via
563 isoflurane inhalation. On study day 0 (SD0) all guinea pigs were challenged with 1000
564 PFU of gpa-EBOV in 0.2 mL of Minimum Essential Medium (MEM) via intraperitoneal
565 (i.p.) injection. The viral dose administered was verified through plaque assay analysis
566 of the prepared virus suspension.

567

568 Dosing for all pyronaridine and all tilorone groups occurred via oral gavage of
569 test/control article on SD0 one hour ($\pm$ 15 minutes) post-challenge. Favipiravir (300
570 mg/kg) was given by oral gavage once daily from SD0 through SD7. For the
571 pyronaridine study on SD 3 and during unscheduled euthanasia blood was collected via
572 retro-orbital bleed. For the tilorone study, blood was collected during scheduled and
573 unscheduled euthanasia. Serum was harvested for viremia measurements via plaque
574 assay.

575

576 Following challenge, animals were monitored daily by visual examination. Clinical
577 scoring and health assessments were performed and documented at each observation
578 using the scoring system wherein: 1= Healthy; 2= Lethargic and ruffled fur, 3= Sore of 2
579 + hunched posture an orbital tightening, 4 = Score of 3 + reluctance to move when
580 stimulated, paralysis, unable to access feed and water normally or $\geq$ 20% body weight

loss. Body weights were measured daily during the dosing period (SD0 – SD7) and then every third day until the study was completed. When animals reached a clinical score of 2, the frequency of clinical observations increased to twice daily, 4-6 hours after the initial observation. When the disease progressed, and the clinical score increased to a 3, the frequency of observations was increased to three times daily. All surviving animals were humanely euthanized on Study Day 21.

Viral load determination. Serum was harvested from guinea pigs that met the euthanasia criteria. Serum harvested for plaque assay analysis was stored frozen (in an ultralow [i.e., -80°C] freezer) until the conclusion of the in-life portion of the animal study, after which samples were batch processed. For this assay, the limit of detection in this assay was 100 PFU/mL. For statistical analysis and graphing all values less than the LOD were assigned a value of one half the LOD.

ACKNOWLEDGMENTS

We gratefully acknowledge the team at Bioduro for their considerable efforts on this project and in particular Mr. Dan Contoit for whom we dedicate this article to his memory.

Dr. Joel S. Freundlich is kindly acknowledged for consultations. We acknowledge Elena Postnikova, Janie Liang, and Shuiqing Yu who performed the *in vitro* testing of compounds against multiple virus strains. Dr. Mupenzi Mumbere is kindly thanked for providing information on drug availability in the Democratic Republic of the Congo.

H.Z., J.D., and M.R.H performed this work as employees of Battelle Memorial Institute (BMI). The findings and conclusions in this report do not necessarily reflect the views or policies of the US Department of Health and Human Services or of the institutions and companies affiliated with the authors.

FUNDING

We kindly acknowledge NIH funding: R21TR001718 from NCATS (PI – Sean Ekins), NIAID CONTRACT NO.: HHSN272201700040I, NIAID TASK ORDER NO.: HHSN27200007 (PI - Peter Madrid). This work was supported by the Division of Intramural Research of the National Institute of Allergy and Infectious Diseases (NIAID); Integrated Research Facility (NIAID, Division of Clinical Research); Battelle Memorial Institute's prime contract with NIAID (Contract # HHSN272200700016I). H.Z., J.D., and M.R.H performed this work as employees of Battelle Memorial Institute (BMI). The findings and conclusions in this report do not necessarily reflect the views or policies of the US Department of Health and Human Services or of the institutions and companies affiliated with the authors.

CONFLICTS OF INTEREST

SE is CEO of Collaborations Pharmaceuticals, Inc. TRL is an employee at Collaborations Pharmaceuticals, Inc. Collaborations Pharmaceuticals, Inc. has obtained FDA orphan drug designations for pyronaridine, tilorone and quinacrine for use against Ebola.

REFERENCES

1. Hernandez HW, Soeung M, Zorn KM, Ashoura N, Mottin M, Andrade CH, Caffrey CR, de Siqueira-Neto JL, Ekins S. 2018. High Throughput and Computational Repurposing for Neglected Diseases. *Pharm Res* 36:27.
2. Ekins S, Williams AJ, Krasowski MD, Freundlich JS. 2011. In silico repositioning of approved drugs for rare and neglected diseases. *Drug Discov Today* 16:298-310.
3. Bai JPF, Hsu CW. 2019. Drug repurposing for Ebola virus disease: principles of consideration and the Animal Rule. *J Pharm Sci* 108:798-806.
4. Baker NC, Ekins S, Williams AJ, Tropsha A. 2018. A bibliometric review of drug repurposing. *Drug Discov Today* 23:661-672.
5. Bai JPF, Hsu CW. 2019. Drug Repurposing for Ebola Virus Disease: Principles of Consideration and the Animal Rule. *J Pharm Sci* 108:798-806.
6. Kouznetsova J, Sun W, Martinez-Romero C, Tawa G, Shinn P, Chen CZ, Schimmer A, Sanderson P, McKew JC, Zheng W, Garcia-Sastre A. 2014. Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs. *Emerg Microbes Infect* 3:e84.

7. Madrid PB, Panchal RG, Warren TK, Shurtleff AC, Endsley AN, Green CE, Kolokoltsov A, Davey R, Manger ID, Gilfillan L, Bavari S, Tanga MJ. 2015. Evaluation of Ebola Virus Inhibitors for Drug Repurposing. *ACS Infect Dis* 1:317-26.
8. Kiley MP, Bowen ET, Eddy GA, Isaacson M, Johnson KM, McCormick JB, Murphy FA, Pattyn SR, Peters D, Prozesky OW, Regnery RL, Simpson DI, Slenczka W, Sureau P, van der Groen G, Webb PA, Wulff H. 1982. Filoviridae: a taxonomic home for Marburg and Ebola viruses? *Intervirology* 18:24-32.
9. Leligidowicz A, Fischer WA, 2nd, Uyeki TM, Fletcher TE, Adhikari NK, Portella G, Lamontagne F, Clement C, Jacob ST, Robinson L, Vanderschuren A, Hajek J, Murthy S, Ferri M, Crozier I, Ibrahima E, Lamah MC, Schieffelin JS, Brett-Major D, Bausch DG, Shindo N, Chan AK, O'Dempsey T, Mishra S, Jacobs M, Dickson S, Lyon GM, 3rd, Fowler RA. 2016. Ebola virus disease and critical illness. *Crit Care* 20:217.
10. Formenty P, Libama F, Epelboin A, Allarangar Y, Leroy E, Moudzeo H, Tarangonia P, Molamou A, Lenzi M, Ait-Ikhlef K, Hewlett B, Roth C, Grein T. 2003. [Outbreak of Ebola hemorrhagic fever in the Republic of the Congo, 2003: a new strategy?]. *Med Trop (Mars)* 63:291-5.
11. Ekins S, Southan C, Coffee M. 2015. Finding small molecules for the 'next Ebola'. *F1000Res* 4:58.

12. Bornholdt ZA, Herbert AS, Mire CE, He S, Cross RW, Wec AZ, Abelson DM, Geisbert JB, James RM, Rahim MN, Zhu W, Borisevich V, Banadyga L, Gunn BM, Agans KN, Wirchnianski AS, Goodwin E, Tierney K, Shestowsky WS, Bohorov O, Bohorova N, Velasco J, Ailor E, Kim D, Pauly MH, Whaley KJ, Alter G, Walker LM, Chandran K, Zeitlin L, Qiu X, Geisbert TW, Dye JM. 2019. A Two-Antibody Pan-Ebolavirus Cocktail Confers Broad Therapeutic Protection in Ferrets and Nonhuman Primates. *Cell Host Microbe* 25:49-58 e5.
13. Jonas O. 2019. Pandemic bonds: designed to fail in Ebola. *Nature* 572:285.
14. Ilunga Kalenga O, Moeti M, Sparrow A, Nguyen VK, Lucey D, Ghebreyesus TA. 2019. The Ongoing Ebola Epidemic in the Democratic Republic of Congo, 2018-2019. *N Engl J Med* doi:10.1056/NEJMSr1904253.
15. Sissoko D, Laouenan C, Folkesson E, M'Lebing AB, Beavogui AH, Baize S, Camara AM, Maes P, Shepherd S, Danel C, Carazo S, Conde MN, Gala JL, Colin G, Savini H, Bore JA, Le Marcis F, Koundouno FR, Petitjean F, Lamah MC, Diederich S, Tounkara A, Poelart G, Berbain E, Dindart JM, Duraffour S, Lefevre A, Leno T, Peyrouset O, Irengue L, Bangoura N, Palich R, Hinzmann J, Kraus A, Barry TS, Berette S, Bongono A, Camara MS, Chanfreau Munoz V, Doumbouya L, Souley H, Kighoma PM, Koundouno FR, Rene L, Loua CM, Massala V, Moumouni K, Provost C, Samake N, Sekou C, et al. 2016. Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. *PLoS Med* 13:e1001967.

16. Kerber R, Lorenz E, Duraffour S, Sissoko D, Rudolf M, Jaeger A, Cisse SD, Camara AM, Miranda O, Castro CM, Akoi Bore J, Raymond Koundouno F, Repits J, Afrough B, Becker-Ziaja B, Hinzmann J, Mertens M, Vitoriano I, Hugh Logue C, Bottcher JP, Pallasch E, Sachse A, Bah A, Cabeza-Cabrerizo M, Nitzsche K, Kuisma E, Michel J, Holm T, Zekeng EG, Cowley LA, Garcia-Dorival I, Hetzelt N, Baum JHJ, Portmann J, Carter L, Yenamaberhan RL, Camino A, Enkirch T, Singethan K, Meisel S, Mazzarelli A, Kosgei A, Kafetzopoulou L, Rickett NY, Patrono LV, Ghebregiorghis L, Arnold U, Colin G, Juchet S, Marchal CL, et al. 2019. Laboratory Findings, Compassionate Use of Favipiravir, and Outcome in Patients With Ebola Virus Disease, Guinea, 2015-A Retrospective Observational Study. *J Infect Dis* 220:195-202.
17. Taylor R, Kotian P, Warren T, Panchal R, Bavari S, Julander J, Dobo S, Rose A, El-Kattan Y, Taubenheim B, Babu Y, Sheridan WP. 2016. BCX4430 - A broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease. *J Infect Public Health* 9:220-6.
18. Lee JS, Adhikari NKJ, Kwon HY, Teo K, Siemieniuk R, Lamontagne F, Chan A, Mishra S, Murthy S, Kiiza P, Hajek J, Bah EI, Lamah MC, Kao R, Fowler RA. 2019. Anti-Ebola therapy for patients with Ebola virus disease: a systematic review. *BMC Infect Dis* 19:376.
19. BBC. 2019. Ebola drugs show '90% survival rate' in breakthrough trial. <https://www.bbc.com/news/world-africa-49326505>. Accessed

20. Madrid PB, Chopra S, Manger ID, Gilfillan L, Keepers TR, Shurtleff AC, Green CE, Iyer LV, Dilks HH, Davey RA, Kolokoltsov AA, Carrion R, Jr., Patterson JL, Bavari S, Panchal RG, Warren TK, Wells JB, Moos WH, Burke RL, Tanga MJ. 2013. A systematic screen of FDA-approved drugs for inhibitors of biological threat agents. PLoS One 8:e60579.
21. Madrid PB, Panchal RG, Warren TK, Shurtleff AC, Endsley AN, Green CE, Kolokoltsov AA, Davey RA, Manger ID, Gilfillan L, Bavari S, Tanga MJ. 2015. Evaluation of Ebola Virus Inhibitors for Drug Repurposing. ACS Inf Dis 1:317-326.
22. Ekins S, Freundlich J, Clark A, Anantpadma M, Davey R, Madrid P. 2015. Machine learning models identify molecules active against Ebola virus in vitro. F1000Res 4:1091.
23. Ekins S, Lingerfelt MA, Comer JE, Freiberg AN, Mirsalis JC, O'Loughlin K, Harutyunyan A, McFarlane C, Green CE, Madrid PB. 2018. Efficacy of Tilorone Dihydrochloride against Ebola Virus Infection. Antimicrob Agents Chemother 62:e01711-17.
24. Lane TR, Comer JE, Freiberg AN, Madrid PB, Ekins S. 2019. Repurposing Quinacrine Against Ebola Virus Infection In vivo. Antimicrob Agents Chemother doi:10.1128/AAC.01142-19.
25. Lane TR, Massey C, Comer JE, Anantpadma M, Freundlich JS, Davey RA, Madrid PB, Ekins S. 2019. Repurposing The Antimalarial Pyronaridine

728 Tetraphosphate To Protect Against Ebola Virus Infection PLoS Negl Trop Dis In
729 Press.

730 26. Anantpadma M, Lane T, Zorn KM, Lingerfelt MA, Clark AM, Freundlich JS,
731 Davey RA, Madrid P, Ekins S. 2019. Ebola Virus Bayesian Machine Learning
732 Models Enable New In Vitro Leads ACS Omega 4:2353-2361.

733 27. Croft SL, Duparc S, Arbe-Barnes SJ, Craft JC, Shin CS, Fleckenstein L,
734 Borghini-Fuhrer I, Rim HJ. 2012. Review of pyronaridine anti-malarial properties
735 and product characteristics. Malar J 11:270.

736 28. Martin RE, Marchetti RV, Cowan AI, Howitt SM, Broer S, Kirk K. 2009.
737 Chloroquine transport via the malaria parasite's chloroquine resistance
738 transporter. Science 325:1680-2.

739 29. Camarda G, Jirawatcharadech P, Priestley RS, Saif A, March S, Wong MHL,
740 Leung S, Miller AB, Baker DA, Alano P, Paine MJ, Bhatia SN, O'Neill PM, Ward
741 SA, Biagini GA. 2019. Antimalarial activity of primaquine operates via a two-step
742 biochemical relay. Nat Commun 10:3226.

743 30. Dziekan JM, Yu H, Chen D, Dai L, Wirjanata G, Larsson A, Prabhu N, Sobota
744 RM, Bozdech Z, Nordlund P. 2019. Identifying purine nucleoside phosphorylase
745 as the target of quinine using cellular thermal shift assay. Sci Transl Med 11.

746 31. Anantpadma M, Kouznetsova J, Wang H, Huang R, Kolokoltssov A, Guha R,
747 Lindstrom AR, Shtanko O, Simeonov A, Maloney DJ, Maury W, LaCount DJ,
748 Jadhav A, Davey RA. 2016. Large-Scale Screening and Identification of Novel

749 Ebola Virus and Marburg Virus Entry Inhibitors. Antimicrob Agents Chemother
750 60:4471-81.

751 32. Homewood CA, Warhurst DC, Peters W, Baggaley VC. 1972. Lysosomes, pH
752 and the anti-malarial action of chloroquine. Nature 235:50-2.

753 33. Jayaraman SD, Ismail S, Nair NK, Navaratnam V. 1997. Determination of
754 pyronaridine in blood plasma by high-performance liquid chromatography for
755 application in clinical pharmacological studies. J Chromatogr B Biomed Sci Appl
756 690:253-7.

757 34. Ramanathan S, Karupiah S, Nair NK, Oliaro PL, Navaratnam V, Wernsdorfer
758 WH, Mansor SM. 2005. A new and simple solid-phase extraction method for LC
759 determination of pyronaridine in human plasma. J Chromatogr B Analyt Technol
760 Biomed Life Sci 824:45-50.

761 35. Rahim MN, Zhang Z, He S, Zhu W, Banadyga L, Safronetz D, Qiu X. 2018.
762 Postexposure Protective Efficacy of T-705 (Favipiravir) Against Sudan Virus
763 Infection in Guinea Pigs. J Infect Dis 218:S649-S657.

764 36. Ekins S, Lingerfelt MA, Comer JE, Freiberg AN, Mirsalis JC, O'Loughlin K,
765 Harutyunyan A, McFarlane C, Green CE, Madrid PB. 2018. Efficacy of Tilorone
766 Dihydrochloride against Ebola Virus Infection. Antimicrob Agents Chemother 62.

767 37. Sissoko D, Laouenan C, Folkesson E, M'Lebing A-B, Beavogui A-H, Baize S,
768 Camara A-M, Maes P, Shepherd S, Danel C, Carazo S, Conde MN, Gala J-L,
769 Colin G, Savini H, Bore JA, Le Marcis F, Koundouno FR, Petitjean F, Lamah M-

C, Diederich S, Tounkara A, Poelart G, Berbain E, Dindart J-M, Duraffour S,
Lefevre A, Leno T, Peyrouset O, Irengue L, Bangoura NF, Palich R, Hinzmann J,
Kraus A, Barry TS, Berette S, Bongono A, Camara MS, Chanfreau Munoz V,
Doubouya L, Souley H, Kighoma PM, Koundouno FR, René L, Loua CM,
Massala V, Moumouni K, Provost C, Samake N, Sekou C, et al. 2016.
Experimental treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A
historically controlled, single-arm proof-of-concept trial in Guinea. PLOS
Medicine 13:e1001967.

38. Smither SJ, Eastaugh LS, Steward JA, Nelson M, Lenk RP, Lever MS. 2014.
Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus
infection in a mouse model. Antiviral Res 104:153-5.

39. Oestereich L, Ludtke A, Wurr S, Rieger T, Munoz-Fontela C, Gunther S. 2014.
Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in
a small animal model. Antiviral Res 105:17-21.

40. Comer JE, Escaffre O, Neef N, Brasel T, Juelich TL, Smith JK, Smith J,
Kalveram B, Perez DD, Massey S, Zhang L, Freiberg AN. 2019. Filovirus
Virulence in Interferon alpha/beta and gamma Double Knockout Mice, and
Treatment with Favipiravir. Viruses 11.

41. Bixler SL, Bocan TM, Wells J, Wetzel KS, Van Tongeren SA, Dong L, Garza NL,
Donnelly G, Cazares LH, Nuss J, Soloveva V, Koistinen KA, Welch L, Epstein C,
Liang LF, Giesing D, Lenk R, Bavari S, Warren TK. 2018. Efficacy of favipiravir

(T-705) in nonhuman primates infected with Ebola virus or Marburg virus.

Antiviral Res 151:97-104.

42. Guedj J, Piorkowski G, Jacquot F, Madelain V, Nguyen THT, Rodallec A, Gunther S, Carbonnelle C, Mentre F, Raoul H, de Lamballerie X. 2018. Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques. PLoS Med 15:e1002535.

43. Bai CQ, Mu JS, Kargbo D, Song YB, Niu WK, Nie WM, Kanu A, Liu WW, Wang YP, Dafee F, Yan T, Hu Y, Deng YQ, Lu HJ, Yang F, Zhang XG, Sun Y, Cao YX, Su HX, Sun Y, Liu WS, Wang CY, Qian J, Liu L, Wang H, Tong YG, Liu ZY, Chen YS, Wang HQ, Kargbo B, Gao GF, Jiang JF. 2016. Clinical and Virological Characteristics of Ebola Virus Disease Patients Treated With Favipiravir (T-705)-Sierra Leone, 2014. Clin Infect Dis 63:1288-1294.

44. Siegel D, Hui HC, Doerffler E, Clarke MO, Chun K, Zhang L, Neville S, Carra E, Lew W, Ross B, Wang Q, Wolfe L, Jordan R, Soloveva V, Knox J, Perry J, Perron M, Stray KM, Barauskas O, Feng JY, Xu Y, Lee G, Rheingold AL, Ray AS, Bannister R, Strickley R, Swaminathan S, Lee WA, Bavari S, Cihlar T, Lo MK, Warren TK, Mackman RL. 2017. Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses. J Med Chem 60:1648-1661.

45. Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB, Fausther-Bovendo H, Wei H, Aviles J, Hiatt E, Johnson A, Morton J, Swope K, Bohorov O, Bohorova

N, Goodman C, Kim D, Pauly MH, Velasco J, Pettitt J, Olinger GG, Whaley K, Xu B, Strong JE, Zeitlin L, Kobinger GP. 2014. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. *Nature* 514:47-53.

46. Corti D, Misasi J, Mulangu S, Stanley DA, Kanekiyo M, Wollen S, Ploquin A, Doria-Rose NA, Staupe RP, Bailey M, Shi W, Choe M, Marcus H, Thompson EA, Cagigi A, Silacci C, Fernandez-Rodriguez B, Perez L, Sallusto F, Vanzetta F, Agatic G, Cameroni E, Kisalu N, Gordon I, Ledgerwood JE, Mascola JR, Graham BS, Muyembe-Tamfun JJ, Trefry JC, Lanzavecchia A, Sullivan NJ. 2016. Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. *Science* 351:1339-42.

47. Sivapalasingam S, Kamal M, Slim R, Hosain R, Shao W, Stoltz R, Yen J, Pologe LG, Cao Y, Partridge M, Sumner G, Lipsich L. 2018. Safety, pharmacokinetics, and immunogenicity of a co-formulated cocktail of three human monoclonal antibodies targeting Ebola virus glycoprotein in healthy adults: a randomised, first-in-human phase 1 study. *Lancet Infect Dis* 18:884-893.

48. Dowall SD, Bosworth A, Watson R, Bewley K, Taylor I, Rayner E, Hunter L, Pearson G, Easterbrook L, Pitman J, Hewson R, Carroll MW. 2015. Chloroquine inhibited Ebola virus replication in vitro but failed to protect against infection and disease in the in vivo guinea pig model. *J Gen Virol* 96:3484-3492.

49. Dyall J, Johnson JC, Hart BJ, Postnikova E, Cong Y, Zhou H, Gerhardt DM, Michelotti J, Honko AN, Kern S, DeWald LE, O'Loughlin KG, Green CE, Mirsalis

834 JC, Bennett RS, Olinger GG, Jr., Jahrling PB, Hensley LE. 2018. In Vitro and In
835 Vivo Activity of Amiodarone Against Ebola Virus. *J Infect Dis* 218:S592-S596.

836 50. Miller JL, Spiro SG, Dowall SD, Taylor I, Rule A, Alonzi DS, Sayce AC, Wright E,
837 Bentley EM, Thom R, Hall G, Dwek RA, Hewson R, Zitzmann N. 2016. Minimal
838 In Vivo Efficacy of Iminosugars in a Lethal Ebola Virus Guinea Pig Model. *PLoS*
839 *One* 11:e0167018.

840 51. Dowall SD, Bewley K, Watson RJ, Vasan SS, Ghosh C, Konai MM, Gausdal G,
841 Lorens JB, Long J, Barclay W, Garcia-Dorival I, Hiscox J, Bosworth A, Taylor I,
842 Easterbrook L, Pitman J, Summers S, Chan-Pensley J, Funnell S, Vipond J,
843 Charlton S, Haldar J, Hewson R, Carroll MW. 2016. Antiviral Screening of
844 Multiple Compounds against Ebola Virus. *Viruses* 8.

845 52. Wec AZ, Bornholdt ZA, He S, Herbert AS, Goodwin E, Wirchnianski AS, Gunn
846 BM, Zhang Z, Zhu W, Liu G, Abelson DM, Moyer CL, Jangra RK, James RM,
847 Bakken RR, Bohorova N, Bohorov O, Kim DH, Pauly MH, Velasco J, Bortz RH,
848 3rd, Whaley KJ, Goldstein T, Anthony SJ, Alter G, Walker LM, Dye JM, Zeitlin L,
849 Qiu X, Chandran K. 2019. Development of a Human Antibody Cocktail that
850 Deploys Multiple Functions to Confer Pan-Ebolavirus Protection. *Cell Host*
851 *Microbe* 25:39-48 e5.

852 53. Rijal P, Elias SC, Machado SR, Xiao J, Schimanski L, O'Dowd V, Baker T, Barry
853 E, Mendelsohn SC, Cherry CJ, Jin J, Labbe GM, Donnellan FR, Rampling T,
854 Dowall S, Rayner E, Findlay-Wilson S, Carroll M, Guo J, Xu XN, Huang KA,
855 Takada A, Burgess G, McMillan D, Popplewell A, Lightwood DJ, Draper SJ,

- Townsend AR. 2019. Therapeutic Monoclonal Antibodies for Ebola Virus Infection Derived from Vaccinated Humans. *Cell Rep* 27:172-186 e7.
54. Madelain V, Guedj J, Mentre F, Nguyen TH, Jacquot F, Oestereich L, Kadota T, Yamada K, Taburet AM, de Lamballerie X, Raoul H. 2017. Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses. *Antimicrob Agents Chemother* 61.
55. Morris CA, Pokorny R, Lopez-Lazaro L, Miller RM, Arbe-Barnes S, Duparc S, Borghini-Fuhrer I, Shin JS, Fleckenstein L. 2014. Pharmacokinetic interaction between pyronaridine-artesunate and metoprolol. *Antimicrob Agents Chemother* 58:5900-8.
56. Johansen LM, Brannan JM, Delos SE, Shoemaker CJ, Stossel A, Lear C, Hoffstrom BG, DeWald LE, Schornberg KL, Scully C, Lehár J, Hensley LE, White JM, Olinger GG. 2013. FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. *Sci Transl Med* 5:190ra79-190ra79.
57. Fischer J, Lullmann H, Lullmann-Rauch R. 1996. Drug-induced lysosomal storage of sulphated glycosaminoglycans. *Gen Pharmacol* 27:1317-24.
58. Tyteca D, Van Der Smissen P, Mettlen M, Van Bambeke F, Tulkens PM, Mingeot-Leclercq MP, Courtoy PJ. 2002. Azithromycin, a lysosomotropic antibiotic, has distinct effects on fluid-phase and receptor-mediated endocytosis, but does not impair phagocytosis in J774 macrophages. *Exp Cell Res* 281:86-100.

- 877 59. Ikeda K, Hirayama M, Hirota Y, Asa E, Seki J, Tanaka Y. 2008. Drug-induced
878 phospholipidosis is caused by blockade of mannose 6-phosphate receptor-
879 mediated targeting of lysosomal enzymes. *Biochem Biophys Res Commun*
880 377:268-74.
- 881 60. Chen F, Song Q, Yu Q. 2018. Axl inhibitor R428 induces apoptosis of cancer
882 cells by blocking lysosomal acidification and recycling independent of Axl
883 inhibition. *Am J Cancer Res* 8:1466-1482.
- 884 61. Duvvuri M, Konkar S, Hong KH, Blagg BS, Krise JP. 2006. A new approach for
885 enhancing differential selectivity of drugs to cancer cells. *ACS Chem Biol* 1:309-
886 15.
- 887 62. Ghosh C, Chaubey S, Tatu U, Haldar J. 2017. Aryl-alkyl-lysines: small molecular
888 membrane-active antiplasmodial agents. *Medchemcomm* 8:434-439.
- 889 63. Zhang K, Xu WW, Zhang Z, Liu J, Li J, Sun L, Sun W, Jiao P, Sang X, Ren Z, Yu
890 Z, Li Y, Feng N, Wang T, Wang H, Yang S, Zhao Y, Zhang X, Wilker PR, Liu W,
891 Liao M, Chen H, Gao Y, Xia X. 2017. The innate immunity of guinea pigs against
892 highly pathogenic avian influenza virus infection. *Oncotarget* 8:30422-30437.
- 893 64. Chepurinov AA, Dadaeva AA, Kolesnikov SI. 2001. Study of the pathogenesis of
894 Ebola fever in laboratory animals with different sensitivity to this virus. *Bull Exp*
895 *Biol Med* 132:1182-6.

65. Mankowski DC, Laddison KJ, Christopherson PA, Ekins S, Tweedie DJ, Lawton MP. 1999. Molecular cloning, expression, and characterization of CYP2D17 from cynomolgus monkey liver. *Arch Biochem Biophys* 372:189-96.
66. Shimada T, Mimura M, Inoue K, Nakamura S, Oda H, Ohmori S, Yamazaki H. 1997. Cytochrome P450-dependent drug oxidation activities in liver microsomes of various animal species including rats, guinea pigs, dogs, monkeys, and humans. *Arch Toxicol* 71:401-8.
67. Volchkov VE, Chepurnov AA, Volchkova VA, Ternovoj VA, Klenk HD. 2000. Molecular characterization of guinea pig-adapted variants of Ebola virus. *Virology* 277:147-55.
68. Cong Y, Dyal J, Hart BJ, DeWald LE, Johnson JC, Postnikova E, Zhou H, Gross R, Rojas O, Alexander I, Josleyn N, Zhang T, Michelotti J, Janosko K, Glass PJ, Flint M, McMullan LK, Spiropoulou CF, Mierzwa T, Guha R, Shinn P, Michael S, Klumpp-Thomas C, McKnight C, Thomas C, Eakin AE, O'Loughlin KG, Green CE, Catz P, Mirsalis JC, Honko AN, Olinger GG, Jr., Bennett RS, Holbrook MR, Hensley LE, Jahrling PB. 2016. Evaluation of the Activity of Lamivudine and Zidovudine against Ebola Virus. *PLoS One* 11:e0166318.
69. Quinn K, Brindley MA, Weller ML, Kaludov N, Kondratowicz A, Hunt CL, Sinn PL, McCray PB, Jr., Stein CS, Davidson BL, Flick R, Mandell R, Staplin W, Maury W, Chiorini JA. 2009. Rho GTPases modulate entry of Ebola virus and vesicular stomatitis virus pseudotyped vectors. *J Virol* 83:10176-86.

917 70. Brouillette RB, Maury W. 2017. Production of Filovirus Glycoprotein-Pseudotyped
 918 Vesicular Stomatitis Virus for Study of Filovirus Entry Mechanisms. Methods Mol
 919 Biol 1628:53-63.

920

921

922

923

FIG 1 Pyronaridine, tilorone and quinacrine efficacy and cytotoxicity dose response relationship against multiple strains of EBOV (Kikwit, Mayinga and Makona) and MARV (Musoke and Angola) in HeLa cells. (EBOV/Kik, Mak, May: MOI 0.21; MARV/Ang: MOI 0.21; MARV/Mus: MOI 0.4).

FIG 2 Guinea pig dose range-finding toxicity and Pharmacokinetics profile of Pyronaridine administered via oral gavage (A,B,C) or by intraperitoneal injection (D,E,F)

938 **FIG 3** Guinea pig dose range-finding efficacy. gaEBOV efficacy data. Data from
 939 favipiravir and vehicle-treated (combined, n=16) groups were combined from our own
 940 two independent studies in order to strengthen their predictive power. (A) The survival
 941 curves between pyronaridine 300 and 600 mg/kg, favipiravir and vehicle. Asterisks
 942 represent significant difference from the vehicle (Log-rank (Mantel-Cox) test;
 943 Pyronaridine p=0.0307; Favipiravir p=0.0014). B. Mean percent body weight change
 944 from SD0 C. Mean clinical scoring results with overlaid percent survival. D. Plaque
 945 assay for viable EBOV in sera (GPs sacrificed based on clinical score) with Dunnett's
 946 T3 multiple comparisons test. Statistical significance was calculated with log-
 947 transformed plaque assay data using a Dunnett's T3 multiple comparisons test
 948 (Forsythe and Welch ANOVA) with the vehicle designated as the control. The difference
 949 from the vehicle was not found to be significant. For the plaque assay gaEBOV viral
 950 load had LLOD of 100 PFU/ml. Quantified values below these were set to 0.5 x LLOD.
 951 Bars and error-bars represents the geometric mean and geometric SD.

Table 1 Pyronaridine, tilorone and quinacrine ($\pm$ SD) show a similar efficacy against multiple strains of EBOV (Kikwit, Mayinga and Makona) and MARV (Musoke and Angola) in HeLa cells. Analysis via a F-test rejects the hypothesis that the CC_{50} and the respective IC_{50} are the same for each of the compounds evaluated (EBOV, Mayinga, tilorone is ambiguous).

Compound	CC_{50} (μM) ^a	Virus	Strain	MOI	IC_{50} (μM) ^b	SI ^c
Pyronaridine	4.11 $\pm$ 0.50	EBOV	Kikwit	0.21	1.30 $\pm$ 0.42	3.2
			Makona	0.21	0.82 $\pm$ 0.19	5.0
			Mayinga	0.21	1.01 $\pm$ 0.58	4.1
		MARV	Angola	0.21	2.72 $\pm$ 0.97	1.6
			Musoke	0.4	1.01 $\pm$ 0.11	4.1
Tilorone	18.04 $\pm$ 3.04	EBOV	Kikwit	0.21	1.48 $\pm$ 0.47	12.2
			Makona	0.21	1.14 $\pm$ 0.38	15.9
			Mayinga	0.21	1.21 $\pm$ 1.07	15.0

Quinacrine	8.62 ± 0.02	MARV	Angola	0.21	4.51 ± 1.93	4.1
			Musoke	0.4	2.05 ± 0.28	8.8
		EBOV	Kikwit	0.21	1.41 ± 0.25	6.1
			Makona	0.21	1.05 ± 0.26	8.2
			Mayinga	0.21	1.48 ± 0.65	5.8
		MARV	Angola	0.21	2.94 ± 0.76	2.9
			Musoke	0.4	1.57 ± 0.17	5.5

^aCytotoxicity was determined in HeLa cells that were mock infected. Data represent average of 3 dose response curves with 3 replicates per dose.

^bEfficacy was determined in HeLa cells infected at an MOI of 0.21. Data represent average of 4-6 dose response curves with 3 replicates per dose.

^cSI=CC₅₀/IC₅₀

Abbreviations: CC₅₀, 50% cytotoxic concentration; IC₅₀, 50 % inhibitory concentration; SI, selectivity index; MOI, multiplicity of infection.

Table 2 Liver microsomal metabolic stability across species

Species		Pyronaridine	Tilorone	Chloroquine	Quinacrine
Mouse	$t_{1/2}$ (min)	>186	102.7	47.3	12.6
	Cl_{int} (μ L min/mg)	<7.4	13.5	29.3	110.0
	R^2	0.65*	0.91	0.96	0.98
Guinea Pig	$t_{1/2}$ (min)	66.1	12.2	132.6	17.1
	Cl_{int} (μ L min/mg)	21.0	113.7	10.5	81.3
	R^2	0.86	1.00	0.90	0.98
Non-Human Primate	$t_{1/2}$ (min)	89.7	94.3	106.8	10.1
	Cl_{int} (μ L min/mg)	15.5	14.7	13.0	137.4
	R^2	0.98	0.98	0.97	0.98
Human	$t_{1/2}$ (min)	122.2	127.1	201.4	27.5
	Cl_{int} (μ L min/mg)	11.4	10.9	6.9	50.5

	R^2	0.81	0.98	0.95	0.97
<p>* Poor fit of the data. Based on previous data (unpublished) using 1 mg LM/rxn, as opposed to 0.5 mg/rx, suggest metabolism in MLM and HLM are very similar</p>					

Table 3 Mean pharmacokinetics data in male guinea pigs treated with pyronaridine

						C_{max} (ng/ml)		AUC_{last} (hr*ng/ml)		AUC_{inf} (hr*ng/ml)	
Dose (mg/kg)	Administration	Sex (n=3)	T_{1/2} (h)	SE	T_{max} (h)	Mean	SE	Mean	SE	Mean	SE
125	IP	M	72.7	9.3	1	523	175	16,565	5269	17,430	5428
600	Oral	M	90.5	3.9	1	1800	348	50,964	4406	58,783	6712